Phase I Clinical Trial of Concurrent Paclitaxel, Carboplatin, and External Beam Chest Irradiation with Glutamine in Patients with Locally Advanced Non-Small Cell Lung Cancer

REFERENCES

• Jemal A., Murray T., Ward E., Samuels A., Tiwari R. C., Ghafoor A., Feuer E. J., Thun M. J. Cancer statistics. CA Cancer J. Clin. 2005; 55: 10–30
   PubMed Web of Science ®Google Scholar
• Carney D. N., Hansen H. H. Non-small-cell lung cancer–stalemate or progress?. N. Engl. J. Med. 2000; 343: 1261–1262
   PubMed Web of Science ®Google Scholar
• Choy H., Akerley W., Safran H., Graziano S., Chung C., et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J. Clin. Oncol. 1998; 16: 3316–3322
   PubMed Web of Science ®Google Scholar
• Belani C. P., Aisner J., Bahri S., Jett J., Day R., et al. Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease. Semin. Oncol. 1996; 23: 113–116
   PubMed Web of Science ®Google Scholar
• Kaplan B., Altynbas M., Eroglu C., Karahacioglu E., Er O., et al. Preliminary results of a phase II study of weekly paclitaxel PTX) and carboplatin CBDCA) administered concurrently with thoracic radiation therapy TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer NSCLC, Am. J. Clin. Oncol. 2004; 27: 603–610
   Web of Science ®Google Scholar
• Jeremic B., Milicic B., Acimovic L., Milisavljevic S. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study. J. Clin. Oncol. 2005; 23: 1144–1151
   PubMed Web of Science ®Google Scholar
• Leong S. S., Fong K. W., Ong Y. K., Foo K. F., Ang P., et al. Chemo-radiotherapy for stage III unresectable non-small cell lung cancer long-term results of a prospective study. Respir. Med. 2004; 98: 1080–1086
   PubMed Web of Science ®Google Scholar
• Choy H., LaPorte K., Knill-Selby E., Mohr P., Shyr Y. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin. Radiat. Oncol. 1999; 9: 90–96
   PubMed Web of Science ®Google Scholar
• Anderson P. M., Schroeder G., Skubitz K. M. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 1998; 83: 1433–1439
   PubMed Web of Science ®Google Scholar
• Cockerham M. B., Weinberger B. B., Lerchie S. B. Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann. Pharmacother. 2000; 34: 300–303
   PubMed Web of Science ®Google Scholar
• Jensen J. C., Schaefer R., Nwokedi E., Bevans D. W., 3rd, Baker M. L., Pappas A. A., Westbrook K. C., Klimberg V. S. Prevention of chronic radiation enteropathy by dietary glutamine. Ann. Surg. Oncol. 1994; 1: 157–163
   PubMed Web of Science ®Google Scholar
• Klimberg V. S., Salloum R. M., Kasper M., Plumley D. A., Dolson D. J., et al. Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation. Arch. Surg. 1990; 125: 1040–1045
   PubMed Web of Science ®Google Scholar
• Klimberg V. S., Souba W. W., Dolson D. J., Salloum R. M., Hautamaki R. D., et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 1990; 66: 62–68
   PubMed Web of Science ®Google Scholar
• Boyle F. M., Wheeler H. R., Shenfield G. M. Glutamate ameliorates experimental vincristine neuropathy. J. Pharmacol. Exp. Ther. 1996; 279: 410–415
   PubMed Web of Science ®Google Scholar
• Boyle F. M., Wheeler H. R., Shenfield G. M. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J. Neurooncol. 1999; 41: 107–116
   PubMed Web of Science ®Google Scholar
• Savarese D., Boucher J., Corey B. Glutamine treatment of paclitaxel-induced myalgias and arthralgias. J. Clin. Oncol. 1998; 16: 3918–3919
   PubMed Web of Science ®Google Scholar
• Savarese D., Al-Zoubi A., Boucher J. Glutamine for irinotecan diarrhea. J. Clin. Oncol. 2000; 18: 450–451
   PubMed Web of Science ®Google Scholar
• Ziegler T. R. Glutamine supplementation in cancer patients receiving bone marrow transplantation and high dose chemotherapy. J. Nutr. 2001; 131: 2578S–2584S, discussion 2590S
   PubMed Web of Science ®Google Scholar
• Ersin S., Tuncyurek P., Esassolak M., Alkanat M., Buke C., et al. The prophylactic and therapeutic effects of glutamine- and arginine-enriched diets on radiation-induced enteritis in rats. J. Surg. Res. 2000; 89: 121–125
   PubMed Web of Science ®Google Scholar
• Belani C. P., Barstis J., Perry M. C., La Rocca R. V., Nattam S. R., et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J. Clin. Oncol. 2003; 21: 2933–2939
   PubMed Web of Science ®Google Scholar
• Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 1992; 326: 524–530
   PubMed Web of Science ®Google Scholar
• Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J. Clin. Oncol. 1996; 14: 1065–1070
   PubMed Web of Science ®Google Scholar
• Jeremic B., Shibamoto Y., Acimovic L., Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J. Clin. Oncol. 1995; 13: 452–458
   PubMed Web of Science ®Google Scholar
• Komaki R., Lee J. S., Milas L., Lee H. K., Fossella F. V., et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int. J. Radiat. Oncol. Biol. Phys. 2004; 58: 1369–1377
   PubMed Web of Science ®Google Scholar
• Werner-Wasik M., Axelrod R. S., Friedland D. P., Hauck W., Rose L. J., et al. Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy. Clin. Lung Cancer 2001; 2: 284–289, discussion 290
   PubMedGoogle Scholar
• Antonadou D., Pepelassi M., Synodinou M., Puglisi M., Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52: 739–747
   PubMed Web of Science ®Google Scholar
• Buntzel J., Glatzel M., Kuttner K., Weinaug R., Frohlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin. Radiat. Oncol. 2002; 12: 4–13
   PubMed Web of Science ®Google Scholar
• Klimberg V. S. How glutaime protects the gut during irradiation. ICCN 1996; 3: 21–25
   Google Scholar
• Gandara D. R., Chansky K., Albain K. S., Leigh B. R., Gaspar L. E., et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J. Clin. Oncol. 2003; 21: 2004–2010
   PubMedGoogle Scholar
• Lau D., Leigh B., Gandara D., Edelman M., Morgan R., et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J. Clin. Oncol. 2001; 19: 442–447
   PubMed Web of Science ®Google Scholar